Multicenter, open, non-randomised phase III clinical study of efficacy and safety of insulin glulisine injected subcutaneously in patients with type 1 diabetes mellitus using also insulin glargine.
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2009
At a glance
- Drugs Insulin glulisine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 26 May 2009 Actual patient number changed from 125 to 104 as reported by ClinicalTrials.gov.
- 26 Oct 2008 Actual patient number (125) added as reported by ClinicalTrials.gov.